Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme ; volume:21 ; number:1 ; day:6 ; month:1 ; year:2020 ; pages:1-15 ; date:12.2020
Respiratory research ; 21, Heft 1 (6.1.2020), 1-15, 12.2020
- Creator
-
Valenzuela, Claudia
Torrisi, Sebastiano Emanuele
Kahn, Nicolas
Quaresma, Manuel
Stowasser, Susanne
Kreuter, Michael
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-019-1269-6
- URN
-
urn:nbn:de:101:1-2020041309020039112091
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 8:50 AM UTC
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Valenzuela, Claudia
- Torrisi, Sebastiano Emanuele
- Kahn, Nicolas
- Quaresma, Manuel
- Stowasser, Susanne
- Kreuter, Michael
- SpringerLink (Online service)
Other Objects (12)
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK